益生菌或合生制剂可改善血液透析患者的炎症标志物
  • 75名血液透析患者随机分为合生制剂组、益生菌组、对照组,干预持续12周;
  • 合生制剂为15g益生元(菊粉、低聚果糖、低聚半乳糖)+5g益生菌(嗜酸乳杆菌T16、两歧双歧杆菌BIA-6、乳双歧杆菌BIA-6、长双歧杆菌LAF-5),益生菌组使用的益生菌相同;
  • 合生制剂组和益生菌组的血清超灵敏c反应蛋白 (hs-CRP)、抗热休克蛋白70和内毒素的平均血清水平比对照组显著降低;
  • 合生制剂组的hs-CRP和IL-6的平均血清水平最低,对改善炎症标志物更有效。
主编推荐语
szx
《Probiotics and Antimicrobial Proteins》上发表的一项益生菌及合生制剂的RCT结果,发现合生制剂及益生菌均可改善血液透析患者的血清炎症标志物水平,而合生制剂的效果更好。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Effects of Synbiotics and Probiotics Supplementation on Serum Levels of Endotoxin, Heat Shock Protein 70 Antibodies and Inflammatory Markers in Hemodialysis Patients: a Randomized Double-Blinded Controlled Trial

合生制剂和益生菌补充对血液透析患者血清内毒素、热休克蛋白70抗体和炎症标志物水平的影响:一项随机双盲对照试验

10.1007/s12602-018-9509-5

2019-01-08, Article

Abstract & Authors:展开

Abstract:收起
The aim of this study was to investigate the effects of probiotic and synbiotic supplementation on serum inflammatory markers, endotoxin, and anti-HSP70 in hemodialysis (HD) patients. This study was a randomized, double-blind, placebo-controlled trial. Seventy-five hemodialysis patients who met the inclusion and exclusion criteria were randomly assigned for 12 weeks to one of the three arms: synbiotics [n = 23; 15 g of prebiotics, 5 g of probiotic powder containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA-6, Bifidobacterium lactis BIA-6, and Bifidobacterium longum LAF-5 (2.7 × 10 CFU/g each)], probiotics [n = 23; 5 g probiotics as in synbiotic group with 15 g of maltodextrin in the sachet as placebo], and placebo [n = 19; 20 g of maltodextrin in the sachet]. Blood and feces were collected at baseline and after intervention. Serum high sensitive C-reactive protein (hs-CRP), interleukin-6, endotoxin, and anti-heat shock protein 70 antibodies (anti-HSP70) were measured. The number of fecal colonies was determined using the plate-counting method. The mean serum level of hs-CRP, anti-HSP70, and endotoxin decreased significantly between groups (p = 0.007, p = 0.037, and p = 0.036, respectively). For the synbiotic group, the mean changes in hs-CRP and IL-6 were significantly lower than for the placebo (p < 0.001 and p < 0.001, respectively) and probiotic group (p = 0.011 and p = 0.008, respectively). Anti-HSP70 mean changes in the synbiotic and probiotic groups differed from the placebo group (p = 0.002 and p = 0.013, respectively). Administration of synbiotics was more effective than probiotics for improvement of inflammatory markers, endotoxin and anti-HSP70 serum levels. Trial registration number: IRCT2017041233393N1.

First Authors:
Neda Haghighat

Correspondence Authors:
Majid Mohammadshahi

All Authors:
Neda Haghighat,Majid Mohammadshahi,Shokouh Shayanpour,Mohammad Hossein Haghighizadeh

评论